FDA asks Texas court to shut down 19 vaccine records lawsuit
Adds comment from FDA, plaintiff in paragraphs 7-9
By Mike Scarcella
Oct 18 (Reuters) -The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to COVID-19 vaccines, arguing that it has already spent more than $3.5 million to produce more than 1 million documents in the case.
The FDA in a filing on Thursday defended the adequacy of the records it provided in the lawsuit, which was filed by scientists who wanted to see licensing information that the agency relied on to approve the Pfizer-BioNTech coronavirus vaccine.
The lawsuit, filed in late 2021, attracted widespread attention after the FDA said early on that it could take decades to process and disclose records to Public Health and Medical Professionals for Transparency, the group that brought the case.
The public records lawsuit said that “the medical and scientific community and the public have a substantial interest in reviewing the data and information underlying the FDA’s approval of the Pfizer Vaccine.”
It said the requested data would help resolve questions about the FDA’s review process.
U.S. District Judge Mark Pittman in an order in early 2022 set an accelerated time frame for the FDA, calling the group's Freedom of Information Act request an issue “of paramount public importance.”
The FDA declined to comment.
Aaron Siri, a lawyer for Public Health and Medical Professionals for Transparency, in a statement on Friday said the fight for records was not over.
“Despite years of litigation, and the Court’s order to produce all clinical trial documents, FDA continues to improperly withhold over a million pages of trial documents," Siri said.
The agency at one point was producing 55,000 pages of records every 30 days in response to court orders in the lawsuit. It said in Thursday's filing seeking to close the case that it set up “unprecedented and extraordinary operations” to comply with Pittman’s directives.
Public Health and Medical Professionals for Transparency, whose members include professors and scientists from Yale, Harvard, UCLA and Brown, has posted thousands of records on its website.
Lawyers for the group said in a recent court filing that they would waive any further challenge to redactions that the FDA made in the more than 1.2 million documents released as part of the lawsuit.
The adequacy of the FDA’s search for records is the remaining contested issue in the lawsuit.
The FDA said it conducted a “reasonable and adequate search for responsive records.” The group is due to respond to the FDA by Nov. 7.
The case is Public Health and Medical Professionals for Transparency v. U.S. Food and Drug Administration, U.S. District Court for the Northern District of Texas, No. 4:21-cv-01058-P.
For plaintiff: Aaron Siri and ElizabethBrehm of Siri & Glimstad
For defendant: Andrew Freidah of the U.S. Justice Department
Read more:
Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA
‘Paramount importance’: Judge orders FDA to hasten release of Pfizer vaccine docs
Wait what? FDA wants 55 years to process FOIA request over vaccine data
Reporting by Mike Scarcella
Asset collegati
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
